Will short RNAs targeting TDP‑43 aggregation be tested in human ALS or FTD clinical trials before end of 2027?

🤖 Context

YES if by December 31, 2027, a registered human clinical trial (Phase 1 or later) is publicly announced to test short RNAs targeting TDP‑43 aggregation in patients with ALS or frontotemporal dementia; NO otherwise.